HighTower Advisors’s Aerie Pharmaceuticals AERI Stock Holding History

HighTower Advisors’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-25,481	Closed	-$287K	–	3562
2021 Q3	$287K	Sell	25,481 -1,741	-6%	-$25.4K	﹤0.01%	2442
2021 Q2	$437K	Buy	27,222 +2,441	+10%	+$41.9K	﹤0.01%	2128
2021 Q1	$441K	Buy	24,781 +7,794	+46%	+$135K	﹤0.01%	2057
2020 Q4	$228K	Buy	+16,987	New	+$205K	﹤0.01%	2120
2020 Q1	–	Sell	-8,984	Closed	-$217K	–	2570
2019 Q4	$217K	Buy	+8,984	New	+$186K	﹤0.01%	1927
2017 Q3	–	Sell	-4,909	Closed	-$256K	–	2385
2017 Q2	$256K	Sell	4,909 -22,517	-82%	-$1.05M	﹤0.01%	1723
2017 Q1	$1.24M	Buy	27,426 +1,907	+7%	+$85.1K	0.01%	938
2016 Q4	$960K	Buy	25,519 +4,395	+21%	+$166K	0.01%	984
2016 Q3	$794K	Buy	+21,124	New	+$466K	0.01%	1014

Other funds holding AERI

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

HighTower Advisors's AERI Position: Q4 2021 in Review

HighTower Advisors sold out of Aerie Pharmaceuticals (AERI) in Q4 2021, closing a stake of 25,481 shares — an estimated $287K sold.

HighTower Advisors first reported a position in AERI in Q3 2016 and held it in 9 quarters. The position peaked at $1.24M in Q1 2017. 129 funds tracked by Wall St. Rank hold AERI as of Q4 2021.

HighTower Advisors reported no remaining Aerie Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
HighTower Advisors sold 25,481 Aerie Pharmaceuticals shares in Q4 2021, an estimated $287K.
HighTower Advisors first reported a position in Aerie Pharmaceuticals in Q3 2016 and held it in 9 quarters.
HighTower Advisors's Aerie Pharmaceuticals position peaked at $1.24M in Q1 2017.
129 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2021.

Based on HighTower Advisors's 13F filing for Q4 2021, filed 10 Feb 2022.